ADAP
Adaptimmune Therapeutics plc
ADAP
(1.2)0,60 USD
-22.74% ROA
-74.84% ROE
-3.19x PER
242.853.289,00 USD
31.42% DER
0% Yield
-25.67% NPM
Adaptimmune Therapeutics plc Stock Analysis
Adaptimmune Therapeutics plc Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
PBV
The stock's low PBV ratio (0.7x) suggests it's undervalued, making it an attractive opportunity for investors. |
|
| 2 |
DER
The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 3 |
Graham Number
The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity. |
|
| 4 |
ROE
Negative ROE (-89.74%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity. |
|
| 5 |
ROA
The stock's ROA (-26.57%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment. |
|
| 6 |
Revenue Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 7 |
Net Profit Growth
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity. |
|
| 8 |
Assets Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 9 |
Dividend Growth
The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns. |
|
| 10 |
Dividend
No dividends from the company in the past three years raises doubts about its profitability for shareholders. |
|
| 11 |
Buffet Intrinsic Value
The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value. |
Adaptimmune Therapeutics plc Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Adaptimmune Therapeutics plc Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2013 | 0 | |
| 2014 | 604.626 | 100% |
| 2015 | 10.721.306 | 94.36% |
| 2016 | 14.198.000 | 24.49% |
| 2017 | 37.833.000 | 62.47% |
| 2018 | 59.505.000 | 36.42% |
| 2019 | 1.122.000 | -5203.48% |
| 2020 | 3.958.000 | 71.65% |
| 2021 | 6.149.000 | 35.63% |
| 2022 | 27.148.000 | 77.35% |
| 2023 | 29.276.000 | 7.27% |
| 2023 | 60.514.653 | 51.62% |
| 2024 | 513.499.008 | 88.22% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2013 | 8.149.770 | |
| 2014 | 12.528.528 | 34.95% |
| 2015 | 23.192.804 | 45.98% |
| 2016 | 63.789.000 | 63.64% |
| 2017 | 87.388.000 | 27% |
| 2018 | 98.269.000 | 11.07% |
| 2019 | 97.501.000 | -0.79% |
| 2020 | 91.568.000 | -6.48% |
| 2021 | 111.090.000 | 17.57% |
| 2022 | 127.726.000 | 13.02% |
| 2023 | 151.152.000 | 15.5% |
| 2023 | 142.601.599 | -6% |
| 2024 | 171.459.996 | 16.83% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2013 | 1.211.596 | |
| 2014 | 2.728.480 | 55.59% |
| 2015 | 11.323.573 | 75.9% |
| 2016 | 23.208.000 | 51.21% |
| 2017 | 31.106.000 | 25.39% |
| 2018 | 43.601.000 | 28.66% |
| 2019 | 43.391.000 | -0.48% |
| 2020 | 45.795.000 | 5.25% |
| 2021 | 57.305.000 | 20.09% |
| 2022 | 63.387.000 | 9.6% |
| 2023 | 64.656.000 | 1.96% |
| 2023 | 71.810.000 | 9.96% |
| 2024 | 76.332.000 | 5.92% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2013 | -9.291.437 | |
| 2014 | -14.117.587 | 34.19% |
| 2015 | -21.829.447 | 35.33% |
| 2016 | -69.513.000 | 68.6% |
| 2017 | -75.238.000 | 7.61% |
| 2018 | -74.555.000 | -0.92% |
| 2019 | -131.760.000 | 43.42% |
| 2020 | -125.811.000 | -4.73% |
| 2021 | -155.679.000 | 19.19% |
| 2022 | -157.890.000 | 1.4% |
| 2023 | -185.152.000 | 14.72% |
| 2023 | -127.908.870 | -44.75% |
| 2024 | 276.601.720 | 146.24% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2013 | 0 | |
| 2014 | 604.626 | 100% |
| 2015 | 10.721.306 | 94.36% |
| 2016 | 14.198.000 | 24.49% |
| 2017 | 37.833.000 | 62.47% |
| 2018 | 59.505.000 | 36.42% |
| 2019 | -96.379.000 | 161.74% |
| 2020 | -87.610.000 | -10.01% |
| 2021 | -104.941.000 | 16.51% |
| 2022 | -100.578.000 | -4.34% |
| 2023 | 29.276.000 | 443.55% |
| 2023 | 50.657.594 | 42.21% |
| 2024 | 502.518.716 | 89.92% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2013 | -8.464.450 | |
| 2014 | -12.702.252 | 33.36% |
| 2015 | -21.588.854 | 41.16% |
| 2016 | -71.579.000 | 69.84% |
| 2017 | -70.138.000 | -2.05% |
| 2018 | -95.514.000 | 26.57% |
| 2019 | -137.165.000 | 30.37% |
| 2020 | -130.092.000 | -5.44% |
| 2021 | -158.090.000 | 17.71% |
| 2022 | -165.456.000 | 4.45% |
| 2023 | -182.404.000 | 9.29% |
| 2023 | -114.312.372 | -59.57% |
| 2024 | 278.084.000 | 141.11% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2013 | 0 | |
| 2014 | 0 | 0% |
| 2015 | -1 | 0% |
| 2016 | -1 | 100% |
| 2017 | -1 | 0% |
| 2018 | -1 | 0% |
| 2019 | -1 | 100% |
| 2020 | -1 | 0% |
| 2021 | -1 | 100% |
| 2022 | -1 | 0% |
| 2023 | -1 | 0% |
| 2023 | -1 | 0% |
| 2024 | 1 | 100% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2013 | -7.924.781 | |
| 2014 | 35.781.926 | 122.15% |
| 2015 | -37.845.360 | 194.55% |
| 2016 | -60.953.000 | 37.91% |
| 2017 | -79.327.000 | 23.16% |
| 2018 | -109.096.000 | 27.29% |
| 2019 | -115.581.000 | 5.61% |
| 2020 | -56.497.000 | -104.58% |
| 2021 | 1.948.000 | 3000.26% |
| 2022 | -171.509.000 | 101.14% |
| 2023 | -146.324.975 | -17.21% |
| 2023 | -45.448.000 | -221.96% |
| 2024 | 46.631.045 | 197.46% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2013 | -7.765.160 | |
| 2014 | 37.231.325 | 120.86% |
| 2015 | -32.736.307 | 213.73% |
| 2016 | -48.168.000 | 32.04% |
| 2017 | -54.315.000 | 11.32% |
| 2018 | -104.388.000 | 47.97% |
| 2019 | -112.507.000 | 7.22% |
| 2020 | -53.591.000 | -109.94% |
| 2021 | 10.729.000 | 599.5% |
| 2022 | -141.769.000 | 107.57% |
| 2023 | -141.426.060 | -0.24% |
| 2023 | -45.159.000 | -213.17% |
| 2024 | 47.385.597 | 195.3% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2013 | 159.621 | |
| 2014 | 1.449.399 | 88.99% |
| 2015 | 5.109.053 | 71.63% |
| 2016 | 12.785.000 | 60.04% |
| 2017 | 25.012.000 | 48.88% |
| 2018 | 4.708.000 | -431.27% |
| 2019 | 3.074.000 | -53.16% |
| 2020 | 2.906.000 | -5.78% |
| 2021 | 8.781.000 | 66.91% |
| 2022 | 29.740.000 | 70.47% |
| 2023 | 4.898.915 | -507.07% |
| 2023 | 289.000 | -1595.13% |
| 2024 | 754.552 | 61.7% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2012 | -125.656 | |
| 2013 | -2.155.638 | 94.17% |
| 2014 | 2.409.987 | 189.45% |
| 2015 | 259.608.761 | 99.07% |
| 2016 | 166.142.000 | -56.26% |
| 2017 | 202.984.000 | 18.15% |
| 2018 | 246.885.000 | 17.78% |
| 2019 | 123.638.000 | -99.68% |
| 2020 | 341.227.000 | 63.77% |
| 2021 | 205.960.000 | -65.68% |
| 2022 | 81.878.000 | -151.54% |
| 2023 | 88.129.000 | 7.09% |
| 2023 | 39.513.000 | -123.04% |
| 2024 | 96.274.000 | 58.96% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2012 | 3.964.439 | |
| 2013 | 1.810.553 | -118.96% |
| 2014 | 55.518.275 | 96.74% |
| 2015 | 300.677.747 | 81.54% |
| 2016 | 234.515.000 | -28.21% |
| 2017 | 281.147.000 | 16.59% |
| 2018 | 276.736.000 | -1.59% |
| 2019 | 181.543.000 | -52.44% |
| 2020 | 451.142.000 | 59.76% |
| 2021 | 469.545.000 | 3.92% |
| 2022 | 328.916.000 | -42.76% |
| 2023 | 296.638.000 | -10.88% |
| 2023 | 282.616.000 | -4.96% |
| 2024 | 321.701.999 | 12.15% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2012 | 4.090.095 | |
| 2013 | 3.966.190 | -3.12% |
| 2014 | 53.108.287 | 92.53% |
| 2015 | 41.068.985 | -29.31% |
| 2016 | 68.373.000 | 39.93% |
| 2017 | 78.163.000 | 12.53% |
| 2018 | 29.851.000 | -161.84% |
| 2019 | 57.905.000 | 48.45% |
| 2020 | 109.915.000 | 47.32% |
| 2021 | 263.585.000 | 58.3% |
| 2022 | 247.038.000 | -6.7% |
| 2023 | 208.509.000 | -18.48% |
| 2023 | 243.103.000 | 14.23% |
| 2024 | 225.428.000 | -7.84% |
Adaptimmune Therapeutics plc Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 0.55
- Net Income per Share
- -0.29
- Price to Earning Ratio
- -3.19x
- Price To Sales Ratio
- 1.72x
- POCF Ratio
- -5.24
- PFCF Ratio
- -5.21
- Price to Book Ratio
- 2.41
- EV to Sales
- 0.55
- EV Over EBITDA
- -1.01
- EV to Operating CashFlow
- -1.77
- EV to FreeCashFlow
- -1.68
- Earnings Yield
- -0.31
- FreeCashFlow Yield
- -0.19
- Market Cap
- 0,24 Bil.
- Enterprise Value
- 0,08 Bil.
- Graham Number
- 1.55
- Graham NetNet
- 0.03
Income Statement Metrics
- Net Income per Share
- -0.29
- Income Quality
- 0.61
- ROE
- -1.17
- Return On Assets
- -0.14
- Return On Capital Employed
- -0.19
- Net Income per EBT
- 0.9
- EBT Per Ebit
- 1.01
- Ebit per Revenue
- -0.28
- Effective Tax Rate
- 0.12
Margins
- Sales, General, & Administrative to Revenue
- 0.51
- Research & Developement to Revenue
- 1.08
- Stock Based Compensation to Revenue
- 0.09
- Gross Profit Margin
- 0.95
- Operating Profit Margin
- -0.28
- Pretax Profit Margin
- -0.28
- Net Profit Margin
- -0.26
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -0.17
- Free CashFlow per Share
- -0.18
- Capex to Operating CashFlow
- -0.05
- Capex to Revenue
- 0.02
- Capex to Depreciation
- 0.2
- Return on Invested Capital
- -0.59
- Return on Tangible Assets
- -0.23
- Days Sales Outstanding
- 61.26
- Days Payables Outstanding
- 242.17
- Days of Inventory on Hand
- 0
- Receivables Turnover
- 5.96
- Payables Turnover
- 1.51
- Inventory Turnover
- 0
- Capex per Share
- 0.01
Balance Sheet
- Cash per Share
- 0,84
- Book Value per Share
- 0,38
- Tangible Book Value per Share
- 0.37
- Shareholders Equity per Share
- 0.38
- Interest Debt per Share
- 0.12
- Debt to Equity
- 0.31
- Debt to Assets
- 0.09
- Net Debt to EBITDA
- 2.12
- Current Ratio
- 3.09
- Tangible Asset Value
- 0,10 Bil.
- Net Current Asset Value
- 0,03 Bil.
- Invested Capital
- 236762998
- Working Capital
- 0,17 Bil.
- Intangibles to Total Assets
- 0
- Average Receivables
- 0,03 Bil.
- Average Payables
- 0,01 Bil.
- Average Inventory
- 0.5
- Debt to Market Cap
- 0.12
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Adaptimmune Therapeutics plc Profile
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
- CEO
- Mr. Adrian G. Rawcliffe
- Employee
- 449
- Address
-
60 Jubilee Avenue
Abingdon, OX14 4RX
Adaptimmune Therapeutics plc Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. William C. A. Bertrand Jr., Esq., J.D. Chief Operating Officer & Chief Compliance Officer |
70 |
| 2 |
Ms. Joanna Brewer Ph.D. Chief Scientific Officer |
70 |
| 3 |
Ms. Kerry Sharp Senior Vice President & General Council |
70 |
| 4 |
Ms. Dana Lynch Senior Director of Corporate Communications |
70 |
| 5 |
Mr. John Lunger Chief Patient Supply Officer |
70 |
| 6 |
Mr. Adrian G. Rawcliffe Chief Executive Officer, Principal Accounting Officer & Director |
70 |
| 7 |
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Co-Founder & Chief Business & Strategy Officer |
70 |
| 8 |
Dr. Juli P. Miller Ph.D. Vice President of Corporate Affairs & Investor Relations |
70 |
| 9 |
Mr. Gavin Hilary James Wood ACA, BA (Hons) Chief Financial Officer |
70 |
| 10 |
Dr. Elliot Norry B.A., M.D. Chief Medical Officer |
70 |
Adaptimmune Therapeutics plc Competitors
